Share 'Roche Shares Update on RG62026 Phase 2/3 Study'
Roche has provided an update to the community regarding the paused recruitment of RG6206, an investigational anti-myostatin adnectin, in ambulatory boys with Duchenne. The company hopes to restart recruitment in the second quarter of this year.
Read the update from Roche:
Dear Duchenne community members,
We would like to share an update of our phase 2/3 clinical study (study 227) with RG620…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this